Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Insys Therapeutics (Insys) has successfully completed phase III efficacy clinical trial for its Fentanyl sublingual spray product candidate. The product is being developed for the treatment of breakthrough cancer pain (BTCP) in opioid-tolerant cancer patients.
Subscribe to our email newsletter
The phase III clinical trial was a multi-center, randomised, double-blind, placebo-controlled study. Dose levels of 100 – 1600mcg were tested in the trial. In the double-blind portion of the trial, patients treated ten episodes of breakthrough cancer pain.
Reportedly, the primary efficacy endpoint was Summed Pain Intensity Differences at 30 minutes after dosing (SPID30). The company said that, of the 97 patients that completed the trial, 93% elected to continue treatment in the extension study.
Richard Rauck, a principal investigator in the phase III study, said: “Cancer patients suffering breakthrough pain found the sublingual (under the tongue) spray of Fentanyl produces very fast, effective, and reproducible pain relief. Patients tolerated the spray very well and were extremely pleased with its overall pain-relieving effect and general lack of side effects.”